NEW HAVEN, Conn.--CuraGen said it signed a target discovery and pharmacogenomics collaboration with the Swiss life-sciences company Hoffmann-La Roche last week. Roche said it will apply CuraGen's bioinformatics and genomics expertise to the discovery of animal nutrition and human health products. The deal is designed to evaluate existing product candidates, discover new targets, and facilitate the development of drugs and diagnostic tests.
Roche will integrate data from CuraGen's SeqCalling and GeneCalling databases into it existing discovery efforts. Terms of the two-year renewable agreement were not disclosed, but Peter Fuller, CuraGen's vice-president of business development, said the successful assessment of late-stage product development candidates would increase the likelihood of CuraGen receiving near-term revenues.